Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin
BackgroundInclisiran is an siRNA-based cholesterol-lowering drug with N-acetylgalactosamine carbohydrate (GalNAc) and is used for the treatment of hypercholesterolemia or dyslipidemia. It reduces LDL-C by 50%, with a convenient dosing schedule and fewer adverse events. Unlike statins, inclisiran has...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1554631/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|